Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis[1][2].
Molecular Weight:
(145.62 kDa)
Purity:
99.46
CAS Number:
[906068-56-2]
Target:
CD28
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
